4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines

This publication has 46 references indexed in Scilit:

• The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors
  Clinical Cancer Research, 2005
• Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo
  Immunology, 2004
• Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T Cells
  Cancer Biology & Therapy, 2003
• 4-1BBL Enhances Anti-tumor Responses in the Presence or Absence of CD28 but CD28 Is Required for Protective Immunity against Parental Tumors
  Cellular Immunology, 2001
• Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse Model
  JNCI Journal of the National Cancer Institute, 2000
• MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope
  European Journal of Immunology, 1999
• Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway
  European Journal of Immunology, 1998
• Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.
  The Journal of Experimental Medicine, 1992
• Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine
  JNCI Journal of the National Cancer Institute, 1992
• RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.
  The Journal of Experimental Medicine, 1992